Amarillo National Bank Has $468,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Amarillo National Bank lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 7.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,178 shares of the biopharmaceutical company’s stock after selling 1,209 shares during the quarter. Amarillo National Bank’s holdings in Pfizer were worth $468,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. TCV Trust & Wealth Management Inc. lifted its stake in Pfizer by 1.3% in the third quarter. TCV Trust & Wealth Management Inc. now owns 34,098 shares of the biopharmaceutical company’s stock valued at $987,000 after buying an additional 450 shares during the period. Bristlecone Advisors LLC lifted its stake in Pfizer by 27.7% in the third quarter. Bristlecone Advisors LLC now owns 116,556 shares of the biopharmaceutical company’s stock valued at $3,373,000 after buying an additional 25,281 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in Pfizer by 1.1% in the third quarter. DekaBank Deutsche Girozentrale now owns 7,398,373 shares of the biopharmaceutical company’s stock valued at $214,684,000 after buying an additional 83,564 shares during the period. GHP Investment Advisors Inc. lifted its stake in Pfizer by 8.8% in the third quarter. GHP Investment Advisors Inc. now owns 13,697 shares of the biopharmaceutical company’s stock valued at $396,000 after buying an additional 1,108 shares during the period. Finally, MCF Advisors LLC lifted its stake in Pfizer by 14.7% in the third quarter. MCF Advisors LLC now owns 18,408 shares of the biopharmaceutical company’s stock valued at $533,000 after buying an additional 2,364 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PFE. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Citigroup assumed coverage on Pfizer in a research report on Friday. They set a “neutral” rating and a $30.00 price target on the stock. Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Barclays raised their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Down 0.7 %

PFE stock opened at $28.45 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business has a 50 day moving average price of $29.08 and a two-hundred day moving average price of $28.51. The company has a market cap of $161.21 billion, a price-to-earnings ratio of -474.17, a P/E/G ratio of 1.01 and a beta of 0.67. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the company earned $0.67 earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.91%. Pfizer’s payout ratio is -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.